Acadian Asset Management LLC Neurocrine Biosciences Inc Transaction History

Acadian Asset Management LLC

$34.5 Billion
Q4 2024

A detailed history of Acadian Asset Management LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Acadian Asset Management LLC holds 2,671 shares of NBIX stock, worth $322,362. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,671

Previous 18,992 85.94%

Holding current value

$322,362

Previous $2.18 Million 83.33%

% of portfolio

0.0%

Previous 0.01%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	SELL	$111.62 - $139.44 $1.82 Million - $2.28 Million	-16,321 Reduced 85.94%	2,671 $364,000
Q3 2024 Nov 12, 2024	BUY	$114.58 - $153.15 $1.7 Million - $2.27 Million	14,828 Added 356.1%	18,992 $2.18 Million
Q2 2024 Aug 06, 2024	BUY	$130.86 - $143.19 $91,340 - $99,946	698 Added 20.14%	4,164 $571,000
Q1 2024 May 10, 2024	SELL	$130.4 - $143.74 $3.62 Million - $3.99 Million	-27,778 Reduced 88.91%	3,466 $478,000
Q4 2023 Feb 13, 2024	SELL	$106.07 - $132.76 $1.65 Million - $2.06 Million	-15,528 Reduced 33.2%	31,244 $4.11 Million
Q3 2023 Nov 13, 2023	BUY	$94.02 - $117.1 $2.14 Million - $2.66 Million	22,741 Added 94.63%	46,772 $5.26 Million
Q2 2023 Aug 07, 2023	SELL	$89.53 - $104.87 $7.49 Million - $8.77 Million	-83,629 Reduced 77.68%	24,031 $2.26 Million
Q1 2023 May 11, 2023	BUY	$94.11 - $123.02 $5.11 Million - $6.68 Million	54,311 Added 101.8%	107,660 $10.9 Million
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $2.16 Million - $2.57 Million	20,253 Added 61.19%	53,349 $6.36 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $3.05 Million - $3.57 Million	33,096 New	33,096 $3.51 Million
Q2 2022 Aug 09, 2022	SELL	$75.79 - $100.07 $22,206 - $29,320	-293 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$72.45 - $94.81 $21,227 - $27,779	293 New	293 $27,000
Q3 2021 Nov 12, 2021	SELL	$86.18 - $99.03 $133,320 - $153,199	-1,547 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$89.43 - $102.27 $272,850 - $312,025	-3,051 Reduced 66.35%	1,547 $151,000
Q1 2021 May 11, 2021	BUY	$87.57 - $119.4 $316,828 - $431,989	3,618 Added 369.18%	4,598 $447,000
Q4 2020 Feb 11, 2021	SELL	$86.91 - $108.33 $889,958 - $1.11 Million	-10,240 Reduced 91.27%	980 $94,000
Q3 2020 Nov 09, 2020	BUY	$96.16 - $135.15 $317,808 - $446,670	3,305 Added 41.76%	11,220 $1.08 Million
Q2 2020 Aug 12, 2020	BUY	$85.09 - $130.36 $577,505 - $884,753	6,787 Added 601.68%	7,915 $964,000
Q1 2020 May 11, 2020	BUY	$75.11 - $113.76 $51,300 - $77,698	683 Added 153.48%	1,128 $98,000
Q4 2019 Feb 06, 2020	BUY	$86.8 - $118.57 $38,626 - $52,763	445 New	445 $48,000
Q2 2019 Aug 08, 2019	SELL	$72.24 - $91.27 $6,573 - $8,305	-91 Closed	0 $0
Q1 2019 May 09, 2019	SELL	$69.31 - $91.53 $25,644 - $33,866	-370 Reduced 80.26%	91 $8,000
Q4 2018 Feb 07, 2019	BUY	$68.32 - $124.36 $31,495 - $57,329	461 New	461 $32,000
Q1 2018 Apr 12, 2018	SELL	$75.88 - $92.43 $7,512 - $9,150	-99 Closed	0 $0
Q4 2017 Jan 18, 2018	BUY	$58.53 - $77.59 $5,794 - $7,681	99	99 $8,000

Others Institutions Holding NBIX

# of Institutions

654

Shares Held

96.5M

Call Options Held

282K

Put Options Held

281K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.5B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.

Account

Acadian Asset Management LLC Neurocrine Biosciences Inc Transaction History